that included widespread health insurance coverage, a National Essential Drug System, and improved medical care at the grassroots level.
14 As a result, access to care and financial protection, particularly for the rural population, has improved substantially during the past decade. 12, 13, 15 However, there is limited information about urban and rural differences in quality of care in China, including treatment patterns and patient outcomes, and how these differences have changed during this period. Understanding these differences can greatly inform healthcare policies by identifying quality gaps and laying a foundation for future quality improvement initiatives across the country.
ST-segment-elevation myocardial infarction (STEMI) is an ideal condition to assess quality of care, not only because an abundance of evidence-based treatments supported by strong guideline recommendations 16, 17 but also because timely treatments and coordinated systems-of-care are fundamental to achieving optimal outcomes. 18, 19 STEMI has been the focus of multiple national quality initiatives, including Hospital Compare and D2B Alliance in the United States, 20 as well as the National Clinical Audit Program in the United Kingdom. Accordingly, we compared use of evidence-based treatments and in-hospital outcomes for STEMI during this dynamic period between urban and rural China in a nationally representative sample of hospitals, to evaluate government efforts to improve health care and reduce disparities.
Methods

Design Overview of China PEACE-Retrospective AMI Study
The design of the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events)-Retrospective AMI study has been published previously. 21 In brief, we created a nationally representative sample of hospitalizations for AMI during 2001, 2006 , and 2011 using stratified 2-stage random sampling. Based on differences in per capita income and health service capacity across urban and rural areas, as well as 3 official economic-geographic regions (Eastern, Central, and Western), we divided mainland China into 5 study strata: eastern-rural, central-rural, western-rural, eastern-urban, and central/ western-urban. 22 In accordance with the official statistical yearbook, 15 we designated an area as urban if it was part of a downtown or suburban district within a direct-controlled municipality (Beijing, Tianjin, Shanghai, and Chongqing) or 1 of the 283 prefectural-level cities, with a median population of 0.91 million (interquartile range, 0.61-1.49 million). Surrounding county-level regions, including counties and county-level cities, were then designated as rural, with a median population of 0.35 million (interquartile range, 0.20-0.58 million).
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Within this framework, mainland China is composed of 287 urban regions and 2010 rural regions. In the first stage, we sampled representative hospitals within urban and rural stratum from 2011 so as to reflect current practices, hereinafter referred to as urban hospitals or rural hospitals and traced this cohort of hospitals backwards to 2006 and 2001 to characterize temporal trends. In the second stage, we sampled AMI cases based on hospitalization databases in each year using a systematic random sampling procedure. Patients with AMI were identified using International Classification of Diseases-clinical modification codes when available, including versions 9 (410.xx) and 10 (I21.xxxx), or through principal discharge diagnosis terms. The International Classification of Diseases coding is performed by trained medical record staff in local hospitals based on the nationwide standardized Chinese edition of International Classification of Diseases code dictionary. Examination of patient databases from 162 participating hospitals yielded 31 601 hospitalizations for AMI (3859 in 2001, 8863 in 2006, and 18 879 in 2011), on which basis we randomly sampled 18 631 cases and acquired medical records for 18 110 (97.2%; Figure 1 ). 21 Clinical information was collected through centralized medical chart abstraction using standardized data definitions. Rigorous monitoring was conducted at each stage to ensure data quality. Data abstraction quality was monitored by randomly auditing 5% of records. The medical record abstraction and data monitoring procedures have been described previously in detail. 21 We also obtained information on the structural characteristics of the hospital and the department via a questionnaire from each participating hospital's principal investigator, typically the director of the Cardiology or Internal Medicine Department (Appendix C in the Data Supplement).
The central ethics committee at the China National Center for Cardiovascular Diseases approved the China PEACE-Retrospective AMI study, with a waiver of patients' written consent because it was not feasible to approach patients hospitalized several years ago in a retrospective study. All collaborating hospitals accepted the central ethics approval except for 5 hospitals, which obtained local approval from internal ethics committees. The study is registered at https:// www.clinicaltrials.gov (NCT01624883).
Study Sample
For this study, we included patients with a definite discharge diagnosis of STEMI, as determined by the combination of clinical discharge diagnosis and electrocardiogram results. A total of 300 medical records were randomly selected and examined by a cardiologist, showing a 94.7% concordance between the abstractors' designation of
WHAT IS KNOWN
• In China, remarkable advances have been made in access to health care during the past decade; meanwhile, important gaps persist in quality of care for ST-segment-elevation myocardial infarction, and the in-hospital mortality has not decreased.
• Prior studies on urban-rural disparities in care for acute myocardial infarction that were all conducted in developed countries showed that patients in rural areas may be less likely to receive evidence-based therapies and may experience worse outcomes.
WHAT THE STUDY ADDS
• For the first time, to our knowledge, we demonstrate that in China, urban-rural disparities in evidencebased treatment for myocardial infarction in China have largely been eliminated. Urban hospitals providing more resource-intensive care did not achieve better outcomes because the risk-adjusted outcomes were not significantly different between urban and rural hospitals in any study year.
• This underscores encouraging trends for achieving more equitable care but also highlights substantial opportunities to improve the quality and value of care in both urban and rural hospitals. Additional efforts focusing on healthcare capacity and insurance coverage in rural areas are needed to reduce the disparity in care with urban areas. • Moreover, rigorous and systematic quality measurement and sophisticated incentives for high-value performance may be necessary to achieve optimized outcomes of patients throughout the country.
AMI subtype and the reviewer (Appendix D in the Data Supplement). For analyses of treatments, tests, and procedures, we excluded patients who were discharged or died within 24 hours after admission because they might not have had the opportunity to receive therapy; we also excluded patients transferred in from other facilities because it was not possible to ascertain reliably early treatments like reperfusion at their prior admission. For the analysis of in-hospital outcomes, we excluded patients who were transferred out because the records of their hospitalizations were truncated; we also excluded patients transferred in because information about their clinical status at the initial presentation was not available. We intended to avoid potential bias in urban-rural comparison introduced by transfers (mostly from rural hospitals to urban hospitals), who may had different risk profile. In addition, patients who were discharged alive within 24 hours of admission were excluded from outcomes analysis because such patients were likely to be misclassified as STEMI.
Variables
Hospital Characteristics
Using a questionnaire completed by each hospital, we assessed the hospital's infrastructure, including an assessment of hospital level (primary, secondary, and tertiary), teaching status (university-affiliated teaching hospital, non-university-affiliated teaching hospital, and nonteaching hospital), infrastructure for advanced cardiac care (coronary care unit and catheterization laboratory), and AMI and coronary revascularization statistics (number of qualified interventionists and coronary artery bypass graft surgery volume performed in 2011). The Chinese government defines hospital level based on the capacity and clinical resources available within the hospital. The annual AMI inpatient volume was ascertained based on hospital databases obtained for the case sampling in each year. 
Patient Characteristics
Collected patient characteristics included age, sex, comorbidities, and clinical profile at presentation. Clinical profile at presentation included systolic blood pressure, heart rate, estimated glomerular filtration rate, and cardiac arrest or cardiogenic shock at presentation. In addition, we computed a mini-global registry of acute coronary events score to summarize patients' severity of disease, based on age, systolic blood pressure on admission, heart rate, ST-segment deviation, cardiac arrest, and elevated cardiac biomarkers.
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Treatments, Procedures, and Diagnostic Testing
We evaluated the use of treatments recommended by the 2010 China guideline for STEMI, 16 which are consistent with the 2007 US guidelines. 24 Treatments included (1) reperfusion therapy, (2) aspirin within 24 hours of admission, (3) clopidogrel within 24 hours of admission, (4) β-blockers within 24 hours of admission, (5) angiotensinconverting enzyme inhibitors or angiotensin receptor blockers during hospitalization, and (6) statins during hospitalization. Rates of utilization were assessed for patients considered ideal for the treatment (ie, those who were clinically eligible and without contraindications, as determined by detailed medical record abstraction [Appendix E in the Data Supplement]). We also evaluated use of laboratory tests (creatinine and troponin), echocardiogram, cardiovascular procedures, therapies that have been proven ineffective (eg, magnesium sulfate), and the use of traditional Chinese medicines.
In-Hospital Outcomes
We measured 2 outcomes that are prespecified: (1) in-hospital mortality or withdrawal from treatment because of a terminal status at discharge and (2) in-hospital composite complications (including death, withdrawal from treatment, reinfarction, shock, ischemic stroke, or congestive heart failure [definition in Appendix F in the Data Supplement]). Because withdrawal from treatment is common in China because of reluctance to die in the hospital among terminally ill patients, we used a composite measure of in-hospital death or withdrawal from treatment, which is also used as a hospital quality measure by the Chinese government. 25 Cardiologists in the coordinating center adjudicated the clinical status of patients who withdrew from treatment, to exclude withdrawal of care for other reasons, such as financial issues. Furthermore, given the potential bias introduced by difference in lengths of stay between patients at urban and rural hospitals, as a sensitivity analysis, we assessed 7-day rates of mortality or withdrawal from treatment, to ensure the validity of comparisons.
Statistical Analysis
Based on the sampling approach, which involved random identification of hospitals throughout China, we were able to calculate estimates reflecting national care patterns and outcomes. These estimates were calculated in each study year with the application of weights proportional to the inverse sampling fraction of hospitals within each stratum and the sampling fraction of patients within each hospital, to account for differences in the sampling fraction for each time period in all analyses. Multiple admissions of the same patient were considered separately in our analysis because we aimed to describe the treatment patterns and outcomes of hospitalizations, rather than patients.
We used weighted percentages to describe categorical variables, medians, and interquartile range to describe continuous variables. To examine urban-rural differences in patient characteristics, treatments, testing, and outcomes and to obtain crude odds ratios and 95% confidence interval (CI), we established univariate logistic regression models providing an unadjusted estimate of the urban/rural variable. We performed Mann-Whitney U tests for urban-rural comparisons of continuous variables.
For temporal changes of patient characteristics and treatments in urban-rural differences across 3 study years (2001, 2006 , and 2011), we constructed multivariable logistic regression models incorporating interaction terms for urban/rural and study periods. To compare the outcomes, we used multilevel logistic regression to account for clustering of patients within sites and adjusted for patients' demographics (age and sex), risk factors or medical history (current smoker, hypertension, diabetes mellitus, dyslipidemia, and history of coronary heart disease or stroke), and clinical profile at presentation (chest discomfort lasting for >10 minutes, duration from symptom onset to admission, as well as systolic blood pressure, heart rate, cardiac arrest, and acute stroke at admission). We categorized continuous variables, such as heart rate, into categorical variables according to clinically meaningful cutoff values. From the multivariable model, we then computed risk-adjusted rates for each outcome of urban and rural hospitals separately. The risk-adjusted rate was calculated as the ratio of observed to predicted outcomes, multiplied by the overall unadjusted rate-a form of indirect standardization. We also compared the risk of death or withdrawal from treatment between urban and rural hospitals with all transferred patients included as a sensitivity analysis.
For age-the only involved variable with missing values (0.1% were unrecorded)-we imputed sample medians. All comparisons were 2-sided, with a P value <0.05 considered statistically significant. Statistical analysis was performed using SPSS, version 13.0 (SPSS, Inc, Chicago), and SAS, version 9.2 (SAS Institute, Cary, NC).
Results
Hospital and Patient Characteristics
Of the 162 participating hospitals, 63 were urban and 99 were rural. Rural hospitals differed significantly from urban hospitals, with smaller volumes of patients and poorer availability of advanced cardiac care (Table 1) .
Within the 162 hospitals, there were a total of 13 815 hospitalizations for STEMI sampled in the 3 study years ( Figure 1 The proportion of women increased over time in rural hospitals (29%, 29%, and 33%, respectively; P for trend, 0.01) but remained unchanged in urban hospitals (29%, 28%, and 28%, respectively; P for trend, 0.3). The prevalence of cardiovascular risk factors among patients increased in both rural and urban hospitals (Table 2) . After excluding patients transferred in, the prehospital delay (time from symptom onset to hospital admission) was similar between rural and urban hospitals (14 
Treatments, Tests, and Procedures
The reperfusion use among ideal candidates in rural hospitals in 2001 and 2006 was lower than in urban hospitals (P<0.001), but by 2011, there was no urban-rural difference in reperfusion rates (P=0.1; Table 3 ). During this period, reperfusion rates increased from 49% in 2001 to 57% in 2011 in rural hospitals (P for trend, 0.001) but decreased from 59% in 2001 to 54% in 2011 in urban hospitals (P for trend, 0.01). In addition, given that patients admitted to rural hospitals in 2011 were more often ideal candidates for reperfusion because of shorter prehospital delays (54% versus 45% in urban hospitals; P<0.001; Appendix G in the Data Supplement), a larger fraction of patients with STEMI there, regardless of the clinical eligibility, received recommended reperfusion therapy in 2011 (30% versus 25%; P<0.001). Among those who received reperfusion therapy in urban hospitals in 2001, 29% received primary percutaneous coronary intervention, whereas fibrinolytic therapy was the only method of reperfusion used in rural hospitals. Over time, primary percutaneous coronary intervention rates increased in both rural and urban areas (P for trend, <0.001 for both); in 2011, 37% of ideal reperfusion patients in urban hospitals received primary percutaneous coronary intervention, as compared with 15% in rural hospitals, wherein fibrinolytic therapy remained the principal mode of reperfusion (P<0.001).
Aspirin and clopidogrel use within 24 hours and statin use during hospitalization were significantly higher among patients in urban hospitals in any study year (P<0.05 for all), with improvements over time in both hospital settings (Table 3) . β-Blocker use within 24 hours was more prevalent among patients treated at urban hospitals in 2001 and 2006 (P<0.05 for both); however, by 2011, rural hospitals had significantly higher use (60% in rural hospitals versus 56% in urban hospitals; P=0.01). Similarly for angiotensin-converting enzyme inhibitors or angiotensin receptor blocker rates, use in urban hospitals was higher in 2001 (64% versus 58%; P=0.047) and 2006 (74% versus 66%; P<0.001) but lower in 2011 (66% versus 68%; P=0.04). The use of traditional Chinese medicines was higher in rural hospitals (P<0.001 for all) and increased in both hospital types over time (P for trend, <0.001 for both).
Rural hospitals had a lower intensity of diagnostic testing, including laboratory tests (troponin and creatinine) and echocardiograms, than urban hospitals (P<0.001 for all) but the urban-rural gap in the use of laboratory tests narrowed over time (P for interaction, <0.001; Table 3 ). Nonprimary percutaneous coronary intervention and cardiac catheterization also increased over time in both urban and rural hospitals (P for trend, <0.001 for all).
In-Hospital Outcomes
A total of 7401 urban patients and 4585 rural patients were included in the outcomes analyses (Figure 1 ). Compared with patients in urban hospitals, the median length of stay for patients in rural hospitals was slightly shorter in both 2001 (12 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 
01).
After adjustment for patient demographics and clinical characteristics, the risk of in-hospital death or withdrawal from treatment did not differ between patients in rural and urban hospitals in all 3 years, with adjusted odds ratios (urban versus rural) of 1. (Figure 2) . The intraclass correlation coefficients of in-hospital death or withdrawal from treatment among hospitals are 0.330, 0.117, and 0.168, respectively, in the 3 study years. Similar results were found in our sensitivity analysis using a 7-day time frame for measurement of outcomes (Appendix H in the Data Supplement). When transferred patients were included in the analyses, the urban versus rural results were similar, with 
Discussion
Our study-the first nationally representative comparison of the hospital care and outcomes for AMI between urban and rural China-found that differences in the use of evidencebased treatments that were present in 2001 have largely been eliminated, but substantial opportunities for improvement persist in both settings. Despite differences in treatment and the availability of advanced facilities, patient outcomes after AMI were similar between urban and rural hospitals in all time periods, indicating that the additional resources available to urban hospitals did not result in greater short-term benefits to patients. In China, patients in rural hospitals were less likely to receive evidence-based STEMI care in 2001, which is similar to what has been reported in developed countries 2, 3, 5, [26] [27] [28] [29] [30] [31] [32] ; but the rates approached parity with urban hospitals by 2011. Preferential investments and policy support for rural areas may have generated these improvements. In 2003, Chinese National Health Statistics indicate that only 21% of rural population was covered by health insurance, and only 6% of inpatient costs, including drugs, were reimbursed. 13 By 2011, with the implementation of the New Rural Cooperative Medical Scheme, access to insurance improved considerably in rural areas, with 98% of the population covered and 44% of inpatient costs reimbursed. 13 Furthermore, the National Essential Drug System established in 2009 ensures the supply of all recommended medications for AMI and provides full reimbursement for them with the exception of clopidogrel. 33, 34 Although the improvements in rural hospitals during the study period are encouraging, the use of evidence-based therapies for AMI remain suboptimal in both rural and urban hospitals, compared with the 77% of contemporary patients with STEMI in the United Kingdom who receive reperfusion therapy. 35 Underused treatment strategies were not only expensive treatments that require advanced techniques and facilities but also less-costly treatments, such as β-blockers. On the contrary, traditional Chinese medicines, which lack data on efficacy and safety, 36 were more commonly used in rural hospitals with more constrained budgets. These examples illustrate that apart from increasing investment, there is a need to focus on improving quality and value of care in both urban and rural hospitals in China.
In contrast to previous studies in developed countries showing that patients admitted with AMI in rural hospitals may experience worse outcomes, [6] [7] [8] patients with STEMI in China had similar outcomes in rural and urban hospitals. Several factors may contribute to these findings. One possibility is that despite greater availability of advanced facilities and higher costs ($3870 per AMI admission in 2011 in urban hospitals versus $1320 in rural hospitals according to National Health Statistics), 15 urban hospitals have not dedicated more resources to systematic approaches to delivering high-quality care. For instance, underuse of lifesaving reperfusion therapy was even more common in urban hospitals in 2011 because their overall reperfusion rates were lower than that of rural hospitals. Differences in patient characteristics do not seem to account for this finding. Contrary to expectations, the comparison of mini-GRACE scores in 2011 showed that patients admitted in rural areas had a higher average baseline risk. Hence, rather than applause for the equitable outcomes between urban and rural areas, our findings seem to suggest a concern that care provided in urban hospitals was of even lower value.
Despite the fact that about half of the Chinese population resides in rural areas, which according to National Health Statistics has a similar mortality burden from AMI compared with urban areas, 15 only about one third of admissions for STEMI in China occurred at rural hospitals in 2011. The Figure 2 . Differences in risk-adjusted rates of in-hospital outcomes between rural and urban hospitals over time. A, In-hospital death or treatment withdrawal. B, In-hospital complications. The covariates included (1) demographic characteristics (age and sex); (2) medical history and risk factors (history of coronary heart disease, myocardial infarction, diabetes mellitus, hypertension, dyslipidemia, and stroke, as well as currently smoking); and (3) clinical features (chest discomfort for >10 min, duration from symptom onset to admission, as well as blood pressure, heart rate, acute stroke, and cardiac arrest at admission). The confidence intervals for risk-adjusted rates were calculated based on the standard error of proportion (the square root of P [1−P]/n).
reasons for this finding are likely multifactorial. One possibility is persistent disparities in access to hospital care: a larger proportion of patients with STEMI in rural areas may die without in-hospital care compared with those in urban areas because rural areas have only half as many hospital beds, physicians, and nurses per 100 000 population as in urban areas. 37 Another explanation is that some rural patients may bypass local hospitals for distant but more advanced urban ones, even for life-threatening conditions, which may also explain much longer prehospital delay in urban hospitals. An in-depth comparison of hospital admission trends in China is warranted to better understand these patterns to optimize the efficiency and equity of AMI healthcare resource allocation.
In addition to advances in access to health care 13 and persistent gaps in quality of care for STEMI identified in prior studies, 38 our study provides insights into the need for a dual strategy to improve medical care in China. For rural areas, investment efforts to improve healthcare capacity and expand insurance coverage, such as the National Essential Drug System and New Rural Cooperative Medical Scheme, have contributed substantially to improved treatment and reduced gaps in care but must continue to reduce the disparity in healthcare resources between rural and urban areas. However, the fact that urban hospitals using more resources did not achieve better outcomes suggests that increasing resources alone is not a complete solution. Rigorous and systematic quality measurement and sophisticated incentives for high-value performance are needed to optimize the quality of care. 39 This study of urban-rural differences highlights the importance of studying various dimensions of care, including admission, treatments, and outcomes, and can serve as a foundation for other countries seeking to eliminate such disparities.
Our findings expand on previous evaluations of the Chinese government's efforts to improve care and reduce disparities during the recent healthcare reform. In addition to improved insurance coverage and access to medications with drug supply system, the Chinese government has established the Hospital Quality Monitoring System and the system for Clinical Pathway Report for Specific Diseases 40 to measure the use of evidence-based therapies for common conditions, including AMI. However, these systems are deemed to have not played the expected function because they lacked robust data analyses and dissemination of their finding. 39 The process quality indicators in our study show a trend of increasing use of higher-cost evidence-based therapies, such as statins and clopidogrel, but not of lower-cost therapies, such as β-blockers and angiotensin-converting enzyme inhibitors. This might suggest that greater resources, rather than quality measurement systems, are the principal cause of improvement in rural areas during the decade of this study. We have elaborated this issue and suggested an improvement strategy of a learning healthcare system to use every healthcare experience to strengthen the system and advance knowledge for the future. 39 Our study also informs the research agenda for understanding and addressing quality gaps. First, there is a constant need to re-evaluate the status of care in order for the health system to identify current deficiencies and react quickly, particularly during such a dynamic period of healthcare reform.
Second, in addition to generating more knowledge about the disparities in quality of care across hospitals in different areas, data on the performance of primary care centers is still largely unavailable and is essential for a more comprehensive picture of health care in China. Third, international comparisons on quality of care are of value for benchmarking performance and developing improvement-focused interventions. 35 This study should be interpreted in the context of several potential limitations. First, clinical characteristics were abstracted from medical records. It is possible that definitions of certain conditions and the completeness of documentation may have varied between urban and rural hospitals; however, there is no reason to suspect so in our analysis. Second, although we adjusted for an array of patient factors, including commonly measured markers of disease severity, unmeasured patient factors could differ between urban and rural patients, which might have influenced our results. Third, shorter length of stay in rural hospitals may bias the study toward lower inhospital event rates. However, we did not find this to be the case in the secondary analysis using a standardized 7-day time frame. Fourth, time to reperfusion, as a key quality indicator, was missing in our analysis because of limitations in documentation of this variable. Instead, we examined admission-to-needle time for fibrinolytic therapy as a surrogate for door-to-needle time. Finally, more recent data and evidence is needed because the access to and quality of AMI treatments may have changed during the past 6 years.
In conclusion, our study demonstrates narrowing treatment gaps and similar patient outcomes after STEMI in urban and rural hospitals in China between 2001 and 2011. This not only underscores encouraging trends for achieving more equitable care but also highlights substantial opportunities to improve the quality and value of care in both settings. To achieve exemplary performance and optimal outcomes, investments to improve capacity and access to care must be accompanied with the implementation of systematic quality measurements and incentive strategies.
